Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

Journal article

within the tumor improving its therapeutic index. Despite this promise, however, single agent-treatments have not been as successful as combination therapies, particularly combining with checkpoint inhibitor antibodies. The antibodies may be delivered by two approaches, either encoded within the OV genome to restrict antibody production to sites of active virus infection or alternatively given alongside OVs as separate treatments. Both approaches have shown promising therapeutic outcomes, and this leads to an interesting question of whether one approach is potentially better than the other. In this review, we provide a brief summary of the combination OV-antibody therapies that target tumor cells, tumor microenvironment and immune cells to help define key parameters influencing which approach is superior, thereby improving insight into the rational design of OV treatment strategies.

Authors: Wan, PK-T; Fernandes, RA; Seymour, LW

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BMJ Publishing Group
• Journal: Journal for ImmunoTherapy of Cancer
• Volume: 11
• Issue: 8
• Pages: e006518-e006518
• Publication date: 2023-08-04
• Acceptance date: 2023-06-25
• DOI: 10.1136/jitc-2022-006518
• EISSN: 2051-1426
• ISSN: 2051-1426
• Language: English
• Keywords: Virology; Immune system; Medicine; Cancer research; Immunology; Computational biology; Biology; Antibody; Oncolytic virus; Virus